pSivida Corp (PSDV):製品パイプライン分析

GlobalDataが発行した調査報告書(DATA8010530)
◆英語タイトル:pSivida Corp (PSDV) - Product Pipeline Analysis, 2017 Update
◆商品コード:DATA8010530
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年12月1日
◆ページ数:37
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥162,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥243,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
pSivida Corp (pSivida) is a specialty pharmaceutical company that offers development of miniaturized, sustained-release drug delivery products and technologies. The company’s products include iluvien, retisert and durasert. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. pSivida’s iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company offers drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. pSivida is headquartered in Watertown, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company pSivida Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
pSivida Corp Company Overview 5
pSivida Corp Company Snapshot 5
pSivida Corp Pipeline Products and Ongoing Clinical Trials Overview 5
pSivida Corp – Pipeline Analysis Overview 8
pSivida Corp – Key Facts 8
pSivida Corp – Major Products and Services 9
pSivida Corp Pipeline Products by Development Stage 10
pSivida Corp Ongoing Clinical Trials by Trial Status 12
pSivida Corp Pipeline Products Overview 14
Durasert – Back Of Eye Disease 14
Durasert – Back Of Eye Disease Product Overview 14
Durasert – Front Of Eye Disease 15
Durasert – Front Of Eye Disease Product Overview 15
Durasert – Knee Osteoarthritis 16
Durasert – Knee Osteoarthritis Product Overview 16
Durasert – Knee Osteoarthritis Clinical Trial 17
Durasert – Posterior Segment Uveitis 18
Durasert – Posterior Segment Uveitis Product Overview 18
Durasert – Posterior Segment Uveitis Clinical Trial 19
Durasert Latanoprost Implant 20
Durasert Latanoprost Implant Product Overview 20
DURASERT With TKI – Wet AMD 21
DURASERT With TKI – Wet AMD Product Overview 21
Next Gen Duraset – Posterior Segment Uveitis 22
Next Gen Duraset – Posterior Segment Uveitis Product Overview 22
Tethadur System 23
Tethadur System Product Overview 23
pSivida Corp – Key Competitors 24
pSivida Corp – Key Employees 25
pSivida Corp – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
pSivida Corp, Recent Developments 27
Nov 07, 2017: pSivida Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution 27
Sep 11, 2017: pSivida Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results 27
Jul 18, 2017: Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences 28
Jun 28, 2017: pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson 29
Jun 22, 2017: pSivida Submits Marketing Authorization Application for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in the European Union 29
Jun 13, 2017: pSivida’s Durasert Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study 30
May 08, 2017: Durasert Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months 31
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results 31
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track 32
May 04, 2017: pSivida Provides Update On Durasert 33
Appendix 34
Methodology 34
About GlobalData 36
Contact Us 36
Disclaimer 37

List of Tables
pSivida Corp Pipeline Products and Ongoing Clinical Trials Overview 5
pSivida Corp Pipeline Products by Equipment Type 6
pSivida Corp Pipeline Products by Indication 7
pSivida Corp Ongoing Clinical Trials by Trial Status 7
pSivida Corp, Key Facts 8
pSivida Corp, Major Products and Services 9
pSivida Corp Number of Pipeline Products by Development Stage 10
pSivida Corp Pipeline Products Summary by Development Stage 11
pSivida Corp Ongoing Clinical Trials by Trial Status 12
pSivida Corp Ongoing Clinical Trials Summary 13
Durasert - Back Of Eye Disease - Product Status 14
Durasert - Back Of Eye Disease - Product Description 14
Durasert - Front Of Eye Disease - Product Status 15
Durasert - Front Of Eye Disease - Product Description 15
Durasert - Knee Osteoarthritis - Product Status 16
Durasert - Knee Osteoarthritis - Product Description 16
Durasert - Knee Osteoarthritis - A Pilot Study of a Dexamethasone Implant System in Humans 17
Durasert - Posterior Segment Uveitis - Product Status 18
Durasert - Posterior Segment Uveitis - Product Description 18
Durasert - Posterior Segment Uveitis - A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye 19
Durasert - Posterior Segment Uveitis - A Phase III, Multi-national, Multi-center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects with Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye 19
Durasert Latanoprost Implant - Product Status 20
Durasert Latanoprost Implant - Product Description 20
DURASERT With TKI - Wet AMD - Product Status 21
DURASERT With TKI - Wet AMD - Product Description 21
Next Gen Duraset - Posterior Segment Uveitis - Product Status 22
Next Gen Duraset - Posterior Segment Uveitis - Product Description 22
Tethadur System - Product Status 23
Tethadur System - Product Description 23
pSivida Corp, Key Employees 25
pSivida Corp, Subsidiaries 26
Glossary 35

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ pSivida Corp (PSDV):製品パイプライン分析(pSivida Corp (PSDV) - Product Pipeline Analysis, 2017 Update)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆